Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 14;12(9):672.
doi: 10.3390/toxics12090672.

In Vitro Hepatic Clearance Evaluations of Per- and Polyfluoroalkyl Substances (PFAS) across Multiple Structural Categories

Affiliations

In Vitro Hepatic Clearance Evaluations of Per- and Polyfluoroalkyl Substances (PFAS) across Multiple Structural Categories

David M Crizer et al. Toxics. .

Abstract

Toxicokinetic (TK) assays and in vitro-in vivo extrapolation (IVIVE) models are New Approach Methods (NAMs) used to translate in vitro points of departure to exposure estimates required to reach equivalent blood concentrations. Per- and polyfluoroalkyl substances (PFAS) are a large chemical class with wide-ranging industrial applications for which only limited toxicity data are available for human health evaluation. To address the lack of TK data, a pooled primary human hepatocyte suspension model was used with targeted liquid chromatography-mass spectrometry to investigate substrate depletion for 54 PFAS. A median value of 4.52 μL/(min x million cells) was observed across those that showed significant clearance, with 35 displaying no substrate depletion. Bayesian modeling propagated uncertainty around clearance values for use in IVIVE models. Structural evaluations showed the fluorotelomer carboxylic acids were the only PFAS carboxylates showing appreciable clearance, and per- and polyfluorosulfonamides were more readily metabolized than other PFAS sulfonates. Biotransformation product prediction, using the chemical transformation simulator, suggested hydrolysis of PFAS sulfonamides to more stable sulfonic acids, which is an important consideration for exposure modeling. This effort greatly expands the PFAS in vitro toxicokinetic dataset, enabling refined TK modeling, in silico tool development, and NAM-based human health evaluations across this important set of emerging contaminants.

Keywords: New Approach Methods (NAMs); PFAS; biotransformation; hepatic clearance; in vitro–in vivo extrapolation (IVIVE); metabolism; toxicokinetics (TK).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Distribution of Hepatic Intrinsic Clearance across Tested PFAS.
Figure 2
Figure 2
Category-based evaluation of PFAS hepatic intrinsic clearance (Clint). Using groupings described in Table 1, experimental point estimates of Clint (circles) and associated means (horizontal bars) and ranges (vertical bars) are displayed. (A) PF carboxylic and propenoic acids. (B) PF sulfonyl groups and FT phosphonic acids (n:2 FTPAs); (C) PFAS Clint from [10]. Abbreviations: PolyF: polyfluorinated; PF: perfluoroalkyl; PE: polyether; FTOH: fluorotelomer alcohol; Pr: primary.
Figure 3
Figure 3
Possible metabolic transformation pathways of PFAS using Chemical Transformation Simulator (CTS). Sulfonamides can transform to sulfonic acids via hydrolysis (A), fluorotelomer carboxylic acids can lead to the formation of unsaturated fluorotelomer carboxylic acids and taurine conjugates (B), and perfluorinated diamines can become fluorinated dioic acids after two hydrolysis reactions (C).

Similar articles

Cited by

References

    1. USEPA Toxic Substances Control Act Reporting and Recordkeeping Requirements for Perfluoroalkyl and Polyfluoroalkyl Substances. Fed. Regist. 2021;88:33926–33966.
    1. Williams A.J., Gaines L.G.T., Grulke C.M., Lowe C.N., Sinclair G.F.B., Samano V., Thillainadarajah I., Meyer B., Patiewicz G., Richard A. Assembly and Curation of Lists of Per- and Polyfluoroalkyl Substances (PFAS) to Support Environmental Science Research. Front. Environ. Sci. 2022;10:1–13. doi: 10.3389/fenvs.2022.850019. - DOI - PMC - PubMed
    1. USEPA . National PFAS Testing Strategy: Identification of Candidate Per- and Polyfluoroalkyl Substances (PFAS) for Testing. USEPA; Washington, DC, USA: 2021.
    1. Houck K.A., Patlewicz G., Richard A.M., Wiulliams A.J., Shobair M.A., Smeltz M., Clifton M.S., Wemore B., Medvedev A., Makarov S. Bioactivity profiling of per- and polyfluoroalkyl substances (PFAS) identifies potential toxicity pathways related to molecular structure. Toxicology. 2021;457:152789. doi: 10.1016/j.tox.2021.152789. - DOI - PubMed
    1. Houck K.A., Paul-Friedman K., Feshuk M., Patlewicz G., Smeltz M., Clifton M.S., Wetmore B.A., Velichko S., Berenyi A., Berg E.L. Evaluation of 147 Perfluoroalkyl Substances for Immunotoxic and Other (patho)Physiological Activities through Phenotypic Screening of Human Primary Cells. volume 40. ALTEX; Terrebonne, QC, Canada: 2023. pp. 248–270. - PMC - PubMed

LinkOut - more resources